Immunotherapy for Glioblastomas
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even with current standard care of triple therapy, consisting of surgical resection, chemo and radiation therapy, the patients' median survival time is only approximately 15 months. Recent practice shows...
Saved in:
Main Authors: | Hu, Wan-Ming (Author), Shan, Frank Y. (Author), Mukherjee, Sanjib (Author), Levacic, Danijela (Author), Huang, Jason H. (Author) |
---|---|
Format: | Ebooks |
Published: |
IntechOpen,
2020-04-02.
|
Subjects: | |
Online Access: | Get Online |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Surgery for Recurrent Glioblastoma
by: Yerramneni, Vamsi Krishna, et al.
Published: (2019) -
Novel Treatment Strategies for Glioblastoma
Published: (2021) -
Glioblastoma: State of the Art and Future Perspectives
Published: (2020) -
Advances in the Biology, Imaging and Therapies for Glioblastoma
Published: (2011) -
Targeted Therapies for Glioblastoma: A Critical Appraisal
Published: (2020)